Spero Therapeutics Statistics
Spero Therapeutics (2HA) Stock Statistics & Valuation Metrics
Total Valuation
Spero Therapeutics has a market cap or net worth of EUR 53.00M. The enterprise value is EUR 79.38M.
- Market Cap
- EUR 53.00M
- Enterprise Value
- EUR 79.38M
Share Statistics
Spero Therapeutics has 58,234,825 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 58,234,825
- Owned by Insiders
- 4.23%
- Owned by Institutions
- 24.69%
Financial Efficiency
Spero Therapeutics’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is -0.04%.
- Return on Equity (ROE)
- 0.15
- Return on Assets (ROA)
- 0.12
- Return on Invested Capital (ROIC)
- -0.04%
- Return on Capital Employed (ROCE)
- -0.00
- Revenue Per Employee
- 2.38M
- Profits Per Employee
- 342.88K
- Employee Count
- 25
- Asset Turnover
- 0.87
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Spero Therapeutics is 7.29. Spero Therapeutics’s PEG ratio is 0.05.
- PE Ratio
- 7.29
- PS Ratio
- 1.38
- PB Ratio
- 1.34
- Price to FCF
- 3.03
- Price to Operating Cash Flow
- 3.02
- PEG Ratio
- 0.05
Income Statement
In the last 12 months, Spero Therapeutics had revenue of 59.62M and earned 8.57M in profits. Earnings per share was 0.15.
- Revenue
- 59.62M
- Gross Profit
- 59.62M
- Operating Income
- -24.00K
- Pretax Income
- 8.83M
- Net Income
- 8.57M
- EBITDA
- 8.83M
- Earnings Per Share (EPS)
- 0.15
Cash Flow
In the last 12 months, operating cash flow was 19.58M and capital expenditures 0, giving a free cash flow of 19.58M billion.
- Operating Cash Flow
- 19.58M
- Free Cash Flow
- 19.58M
- Free Cash Flow per Share
- 0.34
Dividends & Yields
Spero Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 32.49%
- Earnings Yield
- 12.31%
Stock Price Statistics
- Beta
- 1.18
- 52-Week Price Change
- -55.68%
- 50-Day Moving Average
- 0.99
- 200-Day Moving Average
- 1.73
- Relative Strength Index (RSI)
- 44.75
- Average Volume (3m)
- 2,000
Important Dates
Spero Therapeutics upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 12, 2026
- Next Earnings Date
- Nov 16, 2026
- Ex-Dividend Date
- ―
Financial Position
Spero Therapeutics as a current ratio of 7.59, with Debt / Equity ratio of 4.91%
- Current Ratio
- 7.59
- Quick Ratio
- 7.59
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- -4.23
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Spero Therapeutics has paid 261.00K in taxes.
- Income Tax
- 261.00K
- Effective Tax Rate
- 0.03
Enterprise Valuation
Spero Therapeutics EV to EBITDA ratio is 1.50, with an EV/FCF ratio of 0.59.
- EV to Sales
- 0.27
- EV to EBITDA
- 1.50
- EV to Free Cash Flow
- 0.59
- EV to Operating Cash Flow
- 0.59
Balance Sheet
Spero Therapeutics has EUR 50.77M in cash and marketable securities with EUR 2.04M in debt, giving a net cash position of EUR 48.73M billion.
- Cash & Marketable Securities
- EUR 50.77M
- Total Debt
- EUR 2.04M
- Net Cash
- EUR 48.73M
- Net Cash Per Share
- EUR 0.84
- Tangible Book Value Per Share
- EUR 0.76
Margins
Gross margin is 100.00%, with operating margin of 14.02%, and net profit margin of 17.18%.
- Gross Margin
- 100.00%
- Operating Margin
- 14.02%
- Pretax Margin
- 17.79%
- Net Profit Margin
- 17.18%
- EBITDA Margin
- 17.92%
- EBIT Margin
- 17.91%
Analyst Forecast
The average price target for Spero Therapeutics is EUR 5.35, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 5.35
- Price Target Upside
- 478.60% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- 18.44%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 3
- AI Score
- ―
